Quinoline as a privileged scaffold in cancer drug discovery

Current Medicinal Chemistry

Volumn 18, Issue 10, 2011, Pages 1488-1508

  Solomon, V R ^a,b   Lee, H ^a,b,c  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Anticancer activity; Cancer; Chemotherapy; Drug discovery; Quinoline

Indexed keywords

1 METHYL 2 [3 (1 METHYL 1,2 DIHYDROQUINOLIN 2 YLIDEN)PROP 1 ENYL]QUINOLINIUM IODIDE; 2 [2 (5 NITROFURAN 2 YL)VINYL]QUINOLIN 8 OL; 2 AMINO N QUINOLIN 8 YLBENZENESULFONAMIDE; 4 (3 PYRIDIN 2 YL 1H PYRAZOL 4 YL)QUINOLINE; 4 (4 ACETYLPHENYLAMINO) 6 METHOXY 2 PHENYLQUINOLINE; 4 [(2,4 DICHLOROPHENYL)AMINO] 6,7 DIMETHOXY 3 QUINOLINECARBONITRILE; 5 AMINO 6 METHOXY 2 (3',4',5' TRIMETHOXYBENZOYL)QUINOLINE; BOSUTINIB; DOFEQUIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE A; EPOTHILONE B; GLYCOPROTEIN P; HEMATOPOIETIC CELL KINASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; MS 073; N (FURAN 2 YLMETHYL) 6 METHOXY 4 METHYL 5 [3 (TRIFLUOROMETHYL)PHENOXY]QUINOLIN 8 AMINE; N [(2 DIMETHYLAMINO)ETHYL] 2 PHENYLQUINOLINE 8 CARBOXAMIDE; OSI 930; PLATELET DERIVED GROWTH FACTOR; PROTEASOME; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; QUINOLINE DERIVATIVE; TARIQUIDAR; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DERIVATIZATION; DNA REPAIR; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955004745     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795328382     Document Type: Article

References (177)

1. Manske, R.H. The chemistry of quinolines. Chem. Rev, 1942, 30, 113-144.
2. Prescott, T.A.K.; Sadler, I.H.; Kiapranis, R.; Maciver, S.K. Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor. J. Ethnopharmacol., 2007, 109, 289-294. (Pubitemid 44959700)
3. Srivastava, V.; Negi, A.S.; Kumar, J.K.; Gupta, M.M.; Khanuja, S.P.S. Plantbased anticancer molecules: a chemical and biological profile of some important leads. Bioorg. Med. Chem., 2005, 21, 5892-5908 (Pubitemid 41399898)
4. Canel, C.; Moraes, R.M, Dayan, F.E.; Ferreira, D. Molecules of interest: podophyllotoxin. Phytochemistry, 2000, 54,115-120. (Pubitemid 30350846)
5. Du, W. Towards new anticancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids. Tetrahedron, 2003, 59, 8649-8687. (Pubitemid 37237582)
6. Byler, K.G.; Wang, C.; Setzer, W.N. Quinoline alkaloids as intercalative topoisomerase inhibitors. J. Mol. Model., 2009, 15, 1417-1426.
7. Kumar, S.; Bawa, S.; Gupta, H. Biological activities of quinoline derivatives. Mini Rev. Med. Chem., 2009, 9, 1648-1654.
8. Musiol, R.; Serda, M.; Hensel-Bielowka, S.; Polanski, J. Quinoline-based antifungals. Curr Med. Chem., 2010, 17, 1960-1973.
9. Kaur, K.; Jain, M.; Reddy, R. P.; Jain, R. Quinolines and structurally related heterocycles as antimalarials. Eur. J. Med. Chem., 2010, 45, 3245-3264.
10. Solomon, V. R.; Lee, H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol., 2009, 25, 220-233.
11. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7, 606-619. (Pubitemid 44100518)
12. Auger, K.R.; Serunian, L.A.; Soltoff, S.P.; Libby, P.; Cantley, L.C. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell, 1989, 57, 167-175. (Pubitemid 19098878)
13. Cully, M.; You, H.; Levine, A. J.; Mak, T. W. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev Cancer, 2006, 6, 184-192. (Pubitemid 43292562)
14. Auger, K.R.; Luo, L.; Knight, S.D.; Van Aller, G.; Tummino, P.J.; Copeland, R. A.; Diamond, M.; Sutton, D.; Lu, H.; Oleykowski, K.; Sudakin, V.; Dhanak, D.; Jackson, J. R. GSK1059615: A novel inhibitor of phosphoinositide 3-kinase for the treatment of cancer. EORTC-NCI-AACR international conference on molecular targets and cancer, Geneva Palexpo, Geneva, Switzerland, October, 2008.
15. Knight, S.D.; Adams, N.D.; Burgess, J.L.; Chaudhari, A.M.; Darcy, M.G.; Donatelli, C.A.; Luengo, J.I.; Newlander, K.A.; Parrish, C.A.; Ridgers, L.H.; Sarpong, M.A.; Schmidt, SJ.; Van Aller, G.S.; Carson, J.D.; Diamond, M.A.. ; Elkins, P.A.; Gardiner, C.M.; Garver, E.; Gilbert, S.A.; Richard, R.; Gontarek R.R.; Jackson, J.R.; Kershner, K.L.; Luo, L.; Raha, K.; Sherk, C.S.; Sung, C-M.; Sutton, D.; Tummino, P.J.; Wegrzyn, R.J.; Auger, K.R.; Dhanak D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett., 2010, 1, 39-43.
16. David, W. F. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther., 1999, 82, 207-218.
17. Hickey, K.; Grehan, D.; Reid I.M.; O'Briain, S.; Walsh, T.N.; Hennessy, T. P.J. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer, 1994, 74, 1693-1698. (Pubitemid 24301821)
18. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol., 1999, 31, 637-643. (Pubitemid 29248872)
19. Adams, J.A. Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 2001, 101, 2271-2290. (Pubitemid 35373019)
20. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2001, 2, 127-137. (Pubitemid 33674041)
21. Wissner, A.; Overbeek, E.; Reich, M.F.; Floyd, M.B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E.C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W.A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem., 2003, 46, 49-63. (Pubitemid 36043786)
22. Wissner, A.; Berger, D. M.; Boschelli, D.H.; Floyd, M.B.; Greenberger, L.M.; Gruber, B.C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslacis, E.; Wang, Y.F.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6.;7-dialkoxyqurnoline-3-carbonrtrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6.;7-dialkoxyquinazoline inhibitors. J. Med. Chem., 2000, 43, 3244-3256.
23. Wissner, A.; Floyd, M.B.; Rabindran, S.K.; Nilakantan, R.; Greenberger, L.M.; Shen, R.; Wang, YF.; Tsou, H.R. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg. Med. Chem. Lett., 2002, 21, 2893-2897. (Pubitemid 35266757)
24. Wissner, A.; Overbeek, E.; Reich, M.F.; Floyd, M.B.; Johnson, B.D.; Mamuya, N.; Rosfjord, E.C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S.K.; Gruber, BC.; Ye, F.; Hallett, W.A.; Nilakantan, R.; Shen, R.; Wang, Y.F.; Greenberger, L.M.; Tsou, H.R. Synthesis and structure-activity relationships of 6.;7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem., 2003, 46, 49-63. (Pubitemid 36043786)
25. Tsou, H.R.; Overbeek-Klumpers, E.G.; Hallett, W.A.; Reich, M.F.; Floyd, M.B.; Johnson, B.D.; Michalak, R.S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S.K.; Shen, R.; Shi, X.; Wang, YF.; Upeslacis, J.; Wissner, A. Optimization of 6.;7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active.; irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem., 2005, 48, 1107-1131. (Pubitemid 40270454)
26. Rabindran, S.K.; Discafani, C.M.; Rosfjord, E.C.; Baxter, M.; Floyd, M.B.; Golas, J.; Hallett, W.A.; Johnson, B.D.; Nilakantan, R.; Overbeek, E.; Reich, M.F.; Shen, R.; Shi, X.; Tsou, H.R.; Wang, Y.F.; Wissner, A. Antitumor activity of HKI-272.; an orally active.; irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res., 2004, 64, 3958-3965. (Pubitemid 38697310)
27. Wissner, A.; Mansour, T.S. The development of HKI-272 and related compounds for the treatment of cancer. Arch. Pharm. (Weinheim)., 2008, 341, 465-477.
28. Abouzid, K.; Shouman, S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorg. Med. Chem., 2008, 16, 7543-7551.
29. Li, H.H.; Huang, H.; Zhang, X.H.; Luo, X.M.; Lin, L.P.; Jiang, H.L.; Ding, J.; Chen, K.X.; Liu, H. Discovering novel 3-nitroquinolines as a new class of anticancer agents. Acta. Pharmacol. Sin., 2008, 29, 1529-1538.
30. Pawar, V.G.; Sos, M.L.; Rode, H.B.; Rabiller, M.; Heynck, S.; van Otterlo, W.A.; Thomas, R.K.; Rauh, D. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. J. Med. Chem., 2010, 53, 2892-2901.
31. McCormick, F.; Wittinghofer, A. Interactions between Ras proteins and their effectors. Curr. Opin. Biotechnol., 1996, 7, 449-456. (Pubitemid 26265628)
32. Robinson, M.J.; Cobb, M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol., 1997, 9, 180-186. (Pubitemid 27135985)
33. Lewis, T.S.; Shapiro, P.S.; Ahn, N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res., 1998, 74, 49-139. (Pubitemid 28193546)
34. Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J., 2000, 351, 289-305.
35. Sebolt-Leopold, J.S.; Dudley, D.T.; Herrera, R.; Van Becelaere, K.; Wiland, A.; Gowan, R.C.; Tecle, H.; Barrett, S.D.; Bridges, A.; Przybranowski, S.; Leopold, W.R., Saltiel, A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 1999, 5, 810-816. (Pubitemid 29318616)
36. Lackey, K.; Cory, M.; Davis, R.; Frye, S.V.; Harris, P.A.; Hunter, R.N.; Jung, D. K.; McDonald, O.B.; McNutt, R.W.; Peel, M.R.; Rutkowske, R.D.; Veal, J.M.; Wood, E.R. The discovery of potent cRaf-1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 223-226. (Pubitemid 30105376)
37. Wissner, A.; Johnson, B. D.; Reich, M. F.; Floyd, M. B.; Kitchen, D. B.; Tsou, H. R. U.S. Patent 6002008, 1999
38. Chem. Abstr. 1999, 132, 35620.
39. Zhang, N.; Wu, B.; Powell, D.; Wissner, A.; Floyd, M.B.; Kovacs, E.D.; Toral-Barza, L.; Kohler, C. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2825-2828.
40. Zhang, N.; Wu, B.; Eudy, N.; Wang, Y.; Ye, F.; Powell, D.; Wissner, A.; Feldberg, L.R.; Kim, S.C.; Mallon, R.; Kovacs, E.D.; Toral-Barza, L.; Kohler, C. A. MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines. Bioorg. Med. Chem. Lett. 2001, 11, 1407-1411.
41. Berger, D.; Dutia M.; Powell, D.; Wu, B.; Wissner A.; Boschelli, D.H.; Floyd, M.B.; Zhang, N.; Torres, N.; Levin, J.; Du, X.; Wojciechowicz, D.; Discafani, C.; Kohler, C.; Kim, S.C.; Feldberg, L.R.; Collins, K.; Mallon, R. Synthesis and evaluation of 4-anilino-6.;7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorg. Med. Chem. Lett., 2003, 15; 3031-3034. (Pubitemid 37006329)
42. Mallon, R.; Feldberg, L.; Kim, S.; Collins, K.; Wojciechowicz, D.; Kohler, C.; Kovacs, D.; Discafani, C.; Zhang, N.; Wu, B.; Floyd, M.B.; Powell, D.; Berger, D. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. Mol. Cancer Ther., 2004, 3, 755-762. (Pubitemid 39193757)
43. Berger, D.M.; Dutia, M.; Powell, D.; Floyd, M.B.; Torres, N.; Mallon, R.; Wojciechowicz, D.; Kim, S.; Feldberg, L.; Collins, K.; Chaudhary, I. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors. Bioorg. Med. Chem., 2008, 16, 9202-9211.
44. Cernuchova, P.; Vo-Thanh, G.; Milata, V.; Loupy, A.; Jantova, S.; Theiszova, M. Utilization of 2-ethoxymethylene-3-oxobutanenitrile in the synthesis of heterocycles possessing biological activity. Tetrahedron, 2005, 61, 5379-5387. (Pubitemid 40693263)
45. Jantova, S.; Repický, A.; Letasiová, S.; Cipák, L. 4-Amino-3-acetylquinoline-induced apoptosis of murine L1210 leukemia cells involves ROS-mitochondrial-mediated death signaling and activation of p38 MAPK. Cell Biochem. Funct., 2008, 26, 609-619.
46. Elliott, R.L. Blobe, G.C. Role of transforming growth factor beta in human cancer. Clin. Oncol., 2005, 23, 2078-2093. (Pubitemid 46211385)
47. Mauviel, A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol. Med., 2005, 117, 69-80.
48. Muraoka-Cook, R.S.; Dumont, N.; Arteaga, C.L. Dual role of transforming growth factor in mammary tumorigenesis and metastatic progression. Clin. Cancer Res., 2005, 11, 937s-943s. (Pubitemid 40111109)
49. Singh, J.; Chuaqui, C.E.; Boriack-Sjodin, P.A.; Lee, W.C.; Pontz, T.; Corbley, M. J.; Cheung, H.K.; Arduini, R.M.; Mead, J.N.; Newman, M.N.; Papadatos, J.L.; Bowes, S.; Josiah, S.; Ling, L.E. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg. Med. Chem. Lett., 2003, 13, 4355-4359. (Pubitemid 37490817)
50. Sawyer, J.S.; Beight, D.W.; Britt, K.S.; Anderson, B.D.; Campbell, R.M.; Goodson, T.Jr.; Herron, D.K.; Li, H.Y.; McMillen, W.T.; Mort, N.; Parsons, S.; Smith, E.C.; Wagner, J.R.; Yan, L.; Zhang, F.; Yingling J.M. Synthesis and activity of new aryl-and heteroaryl-substituted 5.;6-dihydro-4H-pyrrolo[1.;2-b] pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg. Med. Chem. Lett., 2004, 14, 3581-3584. (Pubitemid 38737172)
51. Li, H.Y.; Wang, Y.; Yan, L.; Campbell, R.M.; Anderson, B.D.; Wagner, J.R.; Yingling, J.M. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5.;6-dihydro-4H- pyrrolo[1.;2-b]pyrazol-3-yl)-quinolines. Bioorg. Med. Chem. Lett., 2004, 14, 3585-3588. (Pubitemid 38737173)
52. Li, H.Y.; McMillen, W.T.; Heap, C.R.; McCann, D.J.; Yan, L.; Campbell, R.M.; Mundla, S.R.; King, C.H.; Dierks, E.A.; Anderson, B.D.; Britt, K.S.; Huss, K.L.; Voss, M.D.; Wang, Y.; Clawson, D.K.; Yingling, J.M.; Sawyer, J.S. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J. Med. Chem., 2008, 51, 2302-2306. (Pubitemid 351503286)
53. Ross R. Platelet-derived growth factor. Lancet, 1989, 1(8648), 1179-1182. (Pubitemid 19138858)
54. Heldin, C.H. Structural and functional studies on platelet-derived growth factor. EMBO J., 1992, 11, 4251-4259.
55. Matsui, T.; Heidaran, M.; Miki, T.; Popescu, N.; Larochelle, W.; Kraus, M.; Pierce, J.; Aaronson, S. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science, 1989, 243, 800-804. (Pubitemid 19062635)
56. Yarden, Y.; Escobedo, J. A.; Kuang, W.J.; Yang-Feng, T.L.; Daniel, T.O.; Tremble, P.M.; Chen, E. Y.; Ando, M.E.; Harkins, R. N.; Francke, U.; Fried, V. A.; Ullrich, A.; Williams, L.T. Structure of the receptor for plateletderived growth factor helps define a family of closely related growth factor receptors. Nature, 1986, 323, 226-232. (Pubitemid 16054308)
57. Escobedo, J.A, Barr, P.J.; Williams, L.T. Role of tyrosine kinase and membrane-spanning domains in signal transduction by the platelet-derived growth factor receptor. Mol. Cell Biol., 1988, 8, 5126-5131.
58. Yarden, Y.; Schlessinger, J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry, 1987, 26, 1434-1442. (Pubitemid 17045874)
59. Rosen, O. M. After insulin binds. Science 1987, 237, 1452-1458. (Pubitemid 17125440)
60. Spada, A.P.; Maguire, M.P.; Persons, P.E.; Myers, M.R. PCT publication no.: WO 92/20642, 1992.
61. Dolle, R.E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J.E.; Baizman, E.; Harris, A. L.; Sawutz, D. G.; Miller, D.; Wang, S.; Faltynek, C. R.; Xie, W.; Sarup, J.; Bode, D. C.; Pagani, E. D.; Silver, P. J. 5,7-Dimethoxy-3-(4- pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem., 1994, 37, 2627-2629. (Pubitemid 24273454)
62. Maguire, M.P.; Sheets, K. R.; McVety, K.; Spada, A.P.; Zilberstein, A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J. Med. Chem., 1994, 37, 2129-2137. (Pubitemid 24228439)
63. Kubo, K.; Shimizu, T.; Ohyama, S.; Murooka, H.; Iwai, A.; Nakamura, K.; Hasegawa, K.; Kobayashi, Y.; Takahashi, N.; Takahashi, K.; Kato, S.; Izawa, T.; Isoe, T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J. Med. Chem., 2005, 48, 1359-1366. (Pubitemid 40364546)
64. Yagi, M.; Kato, S.; Kobayashi, Y.; Kubo, K.; Ohyama, S.; Shimizu, T.; Nishitoba, T.; Isoe, T.; Nakamura, K.; Ohashi, H.; Kobayashi, N.; Iinuma, N.; Osawa, T.; Onose, R.; Osada, H. Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphorylation and PDGF-mediated cellular events by a quinoline derivative. Exp. Cell Res., 1997, 234, 285-293.
65. Kubo, K.; Ohyama, S.; Shimizu, T.; Takami, A.; Murooka, H.; Nishitoba, T.; Kato, S.; Yagi, M.; Kobayashi, Y.; Iinuma, N.; Isoe, T.; Nakamura, K.; Iijima, H.; Osawa, T.; Izawa, T. Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg. Med. Chem., 2003, 11, 5117-5133. (Pubitemid 37352998)
66. Shimizu, T.; Fujiwara, Y.; Osawa, T.; Sakai, T.; Kubo, K.; Kubo, K.; Nishitoba, T.; Kimura, K.; Senga, T.; Murooka, H.; Iwai, A.; Fukushima, K.; Yoshino, T.; Miwa, A. Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. Bioorg. Med. Chem. Lett., 2004, 23, 875-879. (Pubitemid 38167606)
67. Dibb, N.J.; Dilworth, S.M.; Mol, C.D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer, 2004, 4, 718-727. (Pubitemid 39215070)
68. Heinrich, M.C.; Corless, C.L.; Duensing, A.; McGreevey, L.; Chen, C.J.; Joseph, N.; Singer, S.; Griffith, D.J.; Haley, A.; Town, A.; Demetri, G.D.; Fletcher, C. D.; Fletcher, J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299, 708-710. (Pubitemid 36159485)
69. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-2342. (Pubitemid 38702844)
70. Brennan, C.; Dixon, J.A.; Wickens, P.; Kumarasinghe E.; Chuang, C-Y; Kluender, H.C.E.; Hong, Z.; Kreiman, C. 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic WO/2006/096338, 2006.
71. Petti, F.; Thelemann, A.; Kahler, J.; McCormack, S.; Castaldo, L.; Hunt, T.; Nuwaysir, L.; Zeiske, L.; Haack, H.; Sullivan, L.; Garton, A.; Haley, J. D. Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930. Mol. Cancer Ther., 2005, 4, 1186-1197. (Pubitemid 41149566)
72. Garton, A.J.; Crew, A.P.; Franklin, M.; Cooke, A.R.; Wynne, G.M.; Castaldo, L.; Kahler, J.; Winski, S.L.; Franks, A.; Brown, E.N.; Bittner, M.A.; Keily, J.F.; Briner, P.; Hidden, C.; Srebernak, M.C.; Pirrit, C.; O'Connor, M.; Chan, A.; Vulevic, B.; Henninger, D.; Hart, K.; Sennello, R.; Li, A.H.; Zhang, T.; Richardson, F.; Emerson, D.L.; Castelhano, A.L.; Arnold, L.D.; and Gibson, N. W. OSI-930: A novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res., 2006, 66, 1015-1024. (Pubitemid 43165969)
73. Superti-Furga, G.; Courtneidge, S.A. Structure-function relationships in Src family and related protein tyrosine kinases. Bioessays, 1995, 17, 321-330.
74. Courtneidge, S.A. Role of Src in signal transduction pathways. Biochem. Soc. Trans., 2002, 30, 11-17.
75. Susa, M.; Missbach, M.; Green, J. Src inhibitors: Drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci., 2000, 21, 489-495.
76. Lutz, M.P.; Esser, I.B.; Flossmann-Kast, B.B.; Vogelmann, R.; Luhrs, H.; Friess, H.; Buchler, M. W.; Adler, G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun., 1998, 243, 503-508. (Pubitemid 28414054)
77. Boschelli, D.H. Exploitation of the 3-quinolinecarbonitrile template for SRC tyrosine kinase inhibitors. Curr Top. Med. Chem., 2008, 8, 922-934. (Pubitemid 351984713)
78. Boschelli, D.H.; Wang, D.Y.; Ye, F.; Wu, B.; Zhang, N.; Dutia, M.; Powell, D. W.; Wissner, A.; Arndt, K.; Weber, J.M.; Boschelli, F. Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3- quinolinecarbonitriles. J. Med. Chem., 2001, 44, 822-833. (Pubitemid 32171678)
79. Boschelli, D.H.; Ye, F.; Wang, Y.D.; Dutia, M.; Johnson, S.L.; Wu, B.; Miller, K.; Powell, D.W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem., 2001, 44, 3965-3977. (Pubitemid 33051486)
80. Golas, J.M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D.H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res., 2003, 63, 375-381. (Pubitemid 36152495)
81. Boschelli, D.H.; Wang Y.D.; Johnson, S.; Wu, B.; Ye, F.; Barrios Sosa, A.C.; Golas, J.M.; Boschelli, F. 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem., 2004, 47, 1599-1601. (Pubitemid 38380903)
82. Boschelli, D.H.; Wu, B.; Ye, F.; Durutlic, H.; Golas, J.M.; Lucas, J.; Boschelli, F. Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: Identification of potent 7-amino analogs. Bioorg. Med. Chem., 2008, 16, 405-412.
83. Berger, D.; Dutia, M.; Powell, D.; Wissner, A.; DeMorin, F.; Raifeld, Y.; Weber, J.; Boschelli, F. Substituted 4-anilino-7-phenyl-3-quinolin- ecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 2989-2992. (Pubitemid 35266775)
84. Zhang, N.; Wu, B.; Boschelli, D.H,; Golas, J.M.; Boschelli, F. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5071-5074.
85. Boschelli, D.H.; Wang, D.Y.; Ye, F.; Yamashita, A.; Zhang, N.; Powell, D.; Weber, J.; Boschelli, F. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles. Bioorg. Med. Chem. Lett., 2002, 12, 2011-2014. (Pubitemid 34756470)
86. Boschelli, D.H.; Wu, B.; Ye, F.; Wang, Y.; Golas, J.M.; Lucas, J.; Boschelli, F. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J. Med. Chem., 2006, 49, 7868-7876. (Pubitemid 46033676)
87. Barrios Sosa, A.C.; Boschelli, D.H.; Ye, F.; Golas, J.M.; Boschelli, F. Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles. Bioorg. Med. Chem. Lett., 2004, 14, 2155-2158. (Pubitemid 38481381)
88. Barrios Sosa, A.C.; Boschelli, D.H.; Wu, B.; Wang, Y; Golas, J.M. Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor. Bioorg. Med. Chem. Lett., 2005, 15, 1743-1747. (Pubitemid 40312563)
89. Wu, B.; Barrios Sosa, A.C.; Boschelli, D.H.; Boschelli, F.; Honores, E.E.; Golas, J. M.; Powell, D.W.; Wang, YD. 7-(Aryl/heteroar-2-ylethynyl)-4- phenylamino-3-quinolinecarbonitriles as new Src kinase inhibitors: Addition of water solubilizing groups. Bioorg. Med. Chem. Lett., 2006, 16, 3993-3997. (Pubitemid 43903217)
90. Boschelli, D.H.; Barrios Sosa, A.C.; Golas, J.M.; Boschelli, F. Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3- quinolinecarbonitriles: Identification of SKS-927. Bioorg. Med. Chem. Lett, 2007, 17, 1358-1361.
91. Boschelli, D.H.; Wang, D, Wang, Y; Wu, B.; Honores, E.E.; Barrios Sosa, A.C.; Chaudhary, I.; Golas, J.; Lucas, J.; Boschelli F. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 2924-2927.
92. Attié-Bitach, T.; Abitbol, M.; Gérard, M.; Delezoide, A.L.; Augé, J.; Pelet, A.; Amiel, J.; Pachnis, V.; Munnich, A.; Lyonnet, S.; Vekemans, M. Expression of the RET proto-oncogene in human embryos. Am. J. Med. Genet., 1998, 80, 481-486. (Pubitemid 29002014)
93. Avantaggiato, V.; Dathan, N.A.; Grieco, M.; Fabien, N.; Lazzaro, D.; Fusco, A.; Simeone, A.; Santoro, M. Developmental expression of the RET protooncogene. Cell Growth Differ., 1994, 5, 305-311. (Pubitemid 24251380)
94. Enomoto, H.; Crawford, P.A.; Gorodinsky, A.; Heuckeroth, R.O.; Johnson, E. M. Jr.; Milbrandt, J. RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development, 2001, 128, 3963-3974. (Pubitemid 33040604)
95. Schuchardt, A.; D'Agati, V.; Larsson-Blomberg, L.; Costantini, F.; Pachnis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature, 1994, 367(6461), 380-383.
96. Anders, J.; Kjaer, S.; Ibánez, C.F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J. Biol. Chem., 2001, 276, 35808-35817.
97. Graham Robinett, R.; Freemerman, A.J.; Skinner, M.A.; Shewchuk, L.; Lackey, K. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 5886-5893. (Pubitemid 47446214)
98. Ciechanover, A. The ubiquitin-proteasome proteolytic pathway. Cell, 1994, 79, 13-21. (Pubitemid 24309509)
99. Hochstrasser M, Ubiquitin.; proteasomes.; and the regulation of intracellular protein degradation. Curr. Opin. Cell. Biol., 1995, 7, 215-223.
100. Dou, Q.P.; Li, B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist. Updates, 1999, 2, 215-223. (Pubitemid 29526245)
101. Daniel, K.G.; Gupta, P.; Harbach, R.H.; Guida, W.C.; Dou, Q.P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem. Pharmacol., 2004, 67, 1139-1151. (Pubitemid 38296793)
102. Daniel, K.G.; Chen, D.; Orlu, S.; Cui, Q.C.; Miller, F.R.; Dou, Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res., 2005, 7, R897-R908.
103. Adsule, S.; Barve, V.; Chen, D.; Ahmed, F.; Dou, Q.P.; Padhye, S.; Sarkar, F. H. Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J. Med. Chem., 2006, 49, 7242-7246. (Pubitemid 44886011)
104. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4, 253-265. (Pubitemid 38525281)
105. Dark, G.G.; Hill, S.A.; Prise, V.E.; Tozer, G.M.; Pettit, G.R.; Chaplin, D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 1997, 57, 1829-1834. (Pubitemid 27209705)
106. Gaya, A.M.; Rustin, G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol., 2005, 17, 277-290. (Pubitemid 40718658)
107. Siemann, D.W.; Chaplin, D.J.; Walicke, P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs, 2009, 18, 189-197.
108. Tozer, G.M.; Akerman, S.; Cross, N.A.; Barber, P.R.; Bjorndahl, M.A.; Greco, O.; Harris, S.; Hill, S.A.; Honess, D.J.; Ireson, C. R.; Pettyjohn, K.L.; Prise, V.E.; Reyes-Aldasoro, C.C. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-a isoform-producing tumors. Cancer Res., 2008, 68, 2301-2311. (Pubitemid 351521804)
109. Nien, C.Y.; Chen, Y.C.; Kuo, C.C.; Hsieh, H.P.; Chang, C.Y.; Wu, J.S.; Wu, S.Y.; Liou, J.P.; Chang, J.Y. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J. Med. Chem., 2010, 53, 2309-2313.
110. Hfle, G.; Reichenbach, H. In Anticancer Agents from natural products. Cragg, G.M.; Kingston, D.G.I.; Newman, D.J.; Eds. CRC, Boca Raton, 2005, pp. 413-450.
111. Nicolaou, K.C.; Scarpelli, R.; Bollbuck, B.; Werschkun, B.; Pereira, M.M Wartmann, M.; Altmann, K.H.; Zaharevitz, D.; Gussio, R.; Giannakakou, P. Chemical synthesis and biological properties of pyridine epothilones. Chem. Biol., 2000, 7, 593-599.
112. Dietrich, S.A.; Lindauer, R.; Stierlm, C; Gertsch, J.; Matesanz, R.; Notararigo, S.; Díaz, J.F.; Altmann, K.H. Epothilone analogues with benzimidazole and quinoline side chains: chemical synthesis, antiproliferative activity, and interactions with tubulin. Chemistry, 2009, 15, 10144-10157.
113. Zheng, Y.G.; Wu, J.; Chen, Z.; Goodman, M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med. Res. Rev., 2008, 28, 645-687.
114. Manzo, F.; Tambaro, F.P.; Mai, A.; Altucci, L. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin. Ther. Pat., 2009, 19, 761-774.
115. Roth, S.Y.; Denu, J.M.; Allis, C.D. Histone acetyltransferases. Annu. Rev. Biochem., 2001, 70, 81-120. (Pubitemid 32662206)
116. Marmorstein.; R, Roth, S. Y. Histone acetyltransferases: function, structure, and catalysis. Curr Opin. Genet. Dev., 2001, 11, 155-161. (Pubitemid 32209199)
117. Baylin, S.B. Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science, 1997, 277, 1948-1949. (Pubitemid 27449125)
118. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat Rev. Genet., 2002, 3, 415-428. (Pubitemid 34587077)
119. Jones, P.; Altamura, S.; De Francesco, R.; Paz, O.G.; Kinzel, O.; Mesiti, G.; Monteagudo, E.; Pescatore, G.; Rowley, M.; Verdirame, M.; Steinkühler, C. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 2008, 51, 2350-2353. (Pubitemid 351628496)
120. Kinzel, O.; Llauger-Bufi, L.; Pescatore, G.; Rowley, M.; Schultz-Fademrecht, C.; Monteagudo, E.; Fonsi, M.; Gonzalez Paz, O.; Fiore, F.; Steinkühler, C.; Jones, P. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J. Med. Chem., 2009, 52, 3453-3456.
121. Mai, A.; Rotili, D.; Tarantino, D.; Nebbioso, A.; Castellano, S.; Sbardella, G.; Tini, M.; Altucci, L. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorg. Med. Chem. Lett., 2009, 19, 1132-1135.
122. Mai, A.; Rotili, D.; Tarantino, D.; Ornaghi, P.; Tosi, F.; Vicidomini, C.; Sbardella, G.; Nebbioso, A.; Miceli, M, Altucci, L.; Filetici, P. Smallmolecule inhibitors of histone acetyltransferase activity: identification and biological properties. J. Med. Chem., 2006, 49, 6897-6907. (Pubitemid 44749755)
123. Gottesman, M.M.; Fojo, T.; Bates, S.E.; Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer., 2002, 2, 48-58. (Pubitemid 37328807)
124. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv., 2004, 1 , 27-42
125. Juliano, R.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta., 1976, 455, 152-62.
126. Fromm, M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther., 2000, 38, 69-74. (Pubitemid 30077981)
127. Benet, L.Z.; Cummins, C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev., 2001, 50, S3-S11. (Pubitemid 32905352)
128. Fukazawa, N.; Odale, M.; Suzuki, T.; Otsuka, K.; Sato, W.; Tsuruo, T. Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components. EP19890310235, 1989.
129. Suzuki, T.; Fukazawa, N.; San-nohe, K.; Sato, W.; Yano, O.; Tsuruo, T. Structure-activity relation ship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J. Med. Chem., 1997, 40, 2047-2052 (Pubitemid 27265981)
130. Sato, W.; Fukazawa, N.; Suzuki, T.; Yusa, K.; Tsuruo, T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res., 1991, 51, 2024-2032.
131. Sato, W.; Fukazawa, N.; Nakanishi, O.; Baba, M.; Suzuki, T.; Yano, O.; Naito, M.; Tsuruo T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chem. Pharmacol., 1995, 35, 271-277.
132. Sato, W.; Fukazawa, N, Suzuki, T.; Yusa, K.; Tsuruo, T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res., 1991, 51, 2420-2424.
133. Roe, M.; Folkes, A.; Ashworth, P.; Brumwell, J.; Chima, L.; Hunjan, S.; Pretswell, I.; Dangerfield, W.; Ryder, H.; Charlton, P. Reversal of Pglycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett., 1999, 9, 595-600. (Pubitemid 29090660)
134. Mistry, P.; Stewart, A.J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J.A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of Pglycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 2001, 61, 749-58. (Pubitemid 32128642)
135. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with Pglycoprotein. Br. J. Pharmacol., 1999, 128, 403-411. (Pubitemid 29458600)
136. Martin, C.; Berridge, G.; Higgins, C.F.; Callaghan, R. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to Pglycoprotein by an allosteric interaction. Br. J. Pharmacol., 1997, 122, 765-771. (Pubitemid 27453104)
137. Mistry, P.; Stewart, A.J.; Dangerfield, W.; Baker, M.; Liddle, C.; Bootle, D.; Kofler, B.; Laurie, D.; Denny, W.A.; Baguley, B.; Charlton, P.A. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs, 2002, 13, 15-28. (Pubitemid 34169523)
138. Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur. J. Cancer, 2004, 40, 594-605. (Pubitemid 38220779)
139. Labrie, P.; Maddaford, S.P; Lacroix, J.; Catalano, C; Lee, D.H.K, Rakhit, S.; Gaudreault, R.C. In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450. Bioorg. Med. Chem., 2006, 14, 7972-7987. (Pubitemid 44596258)
140. Labrie, P.; Maddaford, S.P.; Lacroix, J.; Catalano, C.; Lee, D.K.; Rakhit, S.; Gaudreault, R.C. In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). Bioorg. Med. Chem., 2007, 15, 3854-3868. (Pubitemid 46661801)
141. Atwell, G.J.; Rewcastle, G.W.; Baguley, B.C.; Denny, W.A. Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem., 1987, 30, 664-669. (Pubitemid 17065201)
142. Rewcastle, G. W.; Denny, W.A.; Baguley, B.C. Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J. Med. Chem., 1987, 30, 843-851. (Pubitemid 17119530)
143. Atwell, G.J.; Baguley, B.C.; Denny, W.A. Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents. J. Med. Chem., 1988, 31, 774-779. (Pubitemid 18097096)
144. Atwell, G.J.; Bos, C.D.; Baguley, B.C.; Denny, W.A. Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides. J. Med. Chem., 1988, 31, 1048-1052.
145. Atwell, G.J.; Baguley, B.C.; Denny, W.A. Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity. J. Med. Chem., 1989, 32, 396-401. (Pubitemid 19061884)
146. Sinhababu, A.K.; Thakker, D.R. Prodrugs of anticancer agents. Adv. Drug Deliv. Rev., 1996, 19, 241-273. (Pubitemid 26191623)
147. Gajski, S.R.; William, R.M. DNA cross-linking agents as antitumor drugs. Chem. Rev., 1998, 98, 2723-2796.
148. Denny, W.A. DNA minor groove alkylating agents. Curr. Med. Chem., 2001, 8, 533-544. (Pubitemid 32409792)
149. Grando, S.A. Mucocutaneous cholinergic system is targeted in mustardinduced vesication. Life Sci., 2003, 72, 2135-2144. (Pubitemid 36298959)
150. Suzukake, K.; Vistica, B.P.; Vistica, D.T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol., 1983, 32, 165-167. (Pubitemid 13168356)
151. Maze, R.; Carney, J.P.; Kelley, M.R.; Glassner, B.J.; Williams, D.A.; Samson, L. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)- 1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl. Acad. Sci. USA., 1996, 93, 206-210.
152. Gourdie, T.A.; Valu, K.K.; Gravatt, G.L.; Boritzki, T.J.; Baguley, B.C.; Wakelin, L.P.G.; Wilson, W.R.; Woodgate, P.D.; Denny, W.A. DNA-directed alkylating agents. 1. Structure-activity relationships for acridinelinked aniline mustards: consequences of varying the reactivity of the mustard. J. Med. Chem., 1990, 33, 1177-1186. (Pubitemid 20115421)
153. Prakash, A.S.; Denny, W.A.; Gourdie, T.A.; Value, K.K.; Woodgate, P.D.; Wakelin, L. P.G. DNA-directed alkylating ligands as potential antitumor agents: sequence specificity of alkylation by intercalating aniline mustards. Biochemistry, 1990, 29, 9799-9807. (Pubitemid 20348511)
154. Gravatt, G.L.; Baguley, B.C.; Wilson, W.R.; Denny, W.A. DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groovetargeted aniline mustard analogues of pibenzimol (Hoechst 33258). J. Med. Chem., 1994, 37, 4338-4345.
155. Kakadiya, R.; Dong, H.; Kumar, A.; Narsinh, D.; Zhang, X.; Chou, T.C.; Lee, T.C.; Shah. A.; Su, T.L. Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazinecarboxamide linker. Bioorg. Med. Chem., 2010, 18, 2285-2299.
156. King, C.L.; Wong, S.K.; Loo, T.L. Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ). Eur. J. Cancer Clin. Oncol, 1984, 20, 261-264. (Pubitemid 14160664)
157. Li, W.; Zhang, Z.W.; Wang, S.X.; Ren, S.M.; Jiang T. Synthesis and analysis of potential DNA intercalators containing quinoline-glucose hybrids. Chem. Biol. Drug Des., 2009, 74, 80-86.
158. Moret, V.; Laras, Y.; Cresteil, T.; Aubert, G.; Ping, D.Q.; Di, C.; Barthélémy-Requin, M.; Béclin, C.; Peyrot, V.; Allegro, D.; Rolland, A.; De Angelis, F.; Gatti, E.; Pierre, P.; Pasquini, L.; Petrucci, E.; Testa, U.; Kraus, J.L. Discovery of a new family of bis-8-hydroxyquinoline substituted benzylamines with pro-apoptotic activity in cancer cells: synthesis, structureactivity relationship, and action mechanism studies. Eur. J. Med. Chem., 2009, 44, 558-567.
159. Madonna, S.; Béclin, C.; Laras, Y.; Moret, V.; Marcowycz, A.; Lamoral-Theys, D.; Dubois, J.; Barthelemy-Requin, M.; Lenglet, G.; Depauw, S.; Cresteil, T.; Aubert, G.; Monnier, V.; Kiss, R.; David-Cordonnier, M.H.; Kraus, J.L. Structure-activity relationships and mechanism of action of antitumor bis 8-hydroxyquinoline substituted benzylamines. Eur. J. Med. Chem., 2010, 45, 623-638.
160. Kim, Y.H.; Shin, K.J.; Lee, T.G.; Kim, E.; Lee, M.S.; Ryu, S.H.; Suh, P.G. G2 arrest and apoptosis by 2-amino-N-quinoline-8-yl-benzenesulfonamide (QBS), a novel cytotoxic compound. Biochem. Pharmacol., 2005, 69, 1333-1341.
161. Solomon, V.R.; Hu, C.; Lee, H. Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach. Bioorg. Med. Chem., 2010, 18, 1563-1572.
162. Solomon, V.R.; Hu, C.; Lee, H. Design and synthesis of chloroquine analogs with anti-breast cancer property. Eur. J. Med. Chem., 2010, 45, 3916-3923.
163. Chang, F.S.; Chen, W.; Wang, C.; Tzeng, C.C.; Chen, Y.L. Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinylquinoline derivatives. Bioorg. Med. Chem., 2010, 18, 124-133.
164. Zhao, Y.L.; Chen, Y.L.; Chang, F.S.; Tzeng, C.C. Synthesis and cytotoxic evaluation of certain 4-anilino-2-phenylquinoline derivatives. Eur. J. Med. Chem., 2005, 40, 792-797.
165. Zhao, Y.L.; Chen, Y.L.; Tzeng, C.C.; Chen, I.L.; Wang, T.C.; Han, C.H. Synthesis and cytotoxic evaluation of certain 4-(phenylamino)furo[2,3-b] quinoline and 2-(furan-2-yl)-4-(phenylamino)quinoline derivatives. Chem. Biodivers., 2005, 2, 205-214.
166. Chen, Y.L.; Zhao, Y.L.; Lu, C.M.; Tzeng, C.C.; Wang, J.P. Synthesis, cytotoxicity, and anti-inflammatory evaluation of 2-(furan-2-yl)-4-(phenoxy) quinoline derivatives. Part 4. Bioorg. Med. Chem., 2006, 14, 4373-4378.
167. Shi, A.; Nguyen, T.A.; Battina, S.K.; Rana, S.; Takemoto, D.J.; Chiang, P. K.; Hua, D.H. Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg. Med. Chem. Lett., 2008, 18, 3364-3368. (Pubitemid 351728090)
168. Somvanshi, R.K.; Subashini, R.; Dhanasekaran, V.; Arulprakash, G.; Das, S.N.; Dey, S. Synthesis, crystal structure, cytotoxic and apoptotic activity of 2,4-dichloro-6-methylquinoline on human oral carcinoma cell line. J. Chem Crystallogr., 2008, 38, 381-386.
169. Hurren, R.; Zavareh R.B.; Dalili, S.; Wood, T.; Rose, D.; Chang, H.; Jamal, N.; Messner, H.; Batey, R.A.; Schimmer, A.D. A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death. Apoptosis, 2008, 13, 748-755.
170. Ashaks, J.; Bankovsky, Y.; Zaruma, D.; Shestakova, I.; Domracheva, I.; Nesterova, A.; Lukevics, E. Synthesis of Quinoline-8-selenol its complex compounds with metals and their cytotoxic activity. Chem. Heterocycl. Comp,, 2004, 40, 776-780.
171. Lukevics, E.; Shestakova, I.; Domracheva, I.; Nesterova A.; Zaruma D.; Ashaks, J. K. Cytotoxicity of metal 8-quinolinethiolates. Chem. Heterocycl. Comp., 2006, 42, 761-766.
172. Lukevics, E.; Shestakova, I.; Domracheva, I.; Yashchenko, E.; Zaruma, D.; Ashaks, J. K. Cytotoxic di(8-quinolyl) disulfides. Chem. Heterocycl. Comp., 2007, 43, 629-633.
173. Lukevics, E.; Shestakova, I.; Domracheva, I.; Yashchenko, E.; Zaruma, D.; Ashaks, J. K. Synthesis and cytotoxicity of metal 4-methyl-8- quinolinethiolates. Chem. Heterocycl. Comp., 2007, 43, 634-636.
174. Zhang, J.Y; Liu, Q.; Xu, Y.; Zhang, Y.; You, X.Z.; Guo, Z.J. N-(8-quinolyl)pyridine-2-carboxamide. Acta Cryst., 2001, C57, 109-110.
175. Zhang, J.; Ke, X.; Tu, C.; Lin, J.; Ding, J.; Lin, L.; Fun, H.K.; You, X.; Guo, Z. Novel Cu(II)-quinoline carboxamide complexes: structural characterization, cytotoxicity and reactivity towards 5'-GMP. Biometals, 2003, 16, 485-496. (Pubitemid 36356781)
176. Hu, C.; Solomon, V.R.; Cano, P.; Lee, H. A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. Eur. J. Med. Chem., 2010, 45, 705-709.
177. Hu, C.; Solomon, V.R.; Ulibarri, G, Lee, H. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg. Med. Chem., 2008, 16, 7888-7893.